Analysts Set Insmed Incorporated (NASDAQ:INSM) PT at $79.19

Shares of Insmed Incorporated (NASDAQ:INSM) have earned an average recommendation of “Buy” from the sixteen ratings firms that are presently covering the firm, MarketBeat Ratings reports. Sixteen analysts have rated the stock with a buy rating. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $79.19.

A number of analysts have recently weighed in on the company. Mizuho increased their price objective on Insmed from $36.00 to $82.00 and gave the company a “buy” rating in a research note on Friday, June 7th. Morgan Stanley boosted their price objective on shares of Insmed from $60.00 to $85.00 and gave the company an “overweight” rating in a research report on Friday, July 12th. Barclays increased their target price on shares of Insmed from $40.00 to $63.00 and gave the stock an “overweight” rating in a report on Wednesday, May 29th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Insmed in a research report on Thursday, June 20th. Finally, HC Wainwright reiterated a “buy” rating and issued a $90.00 price objective on shares of Insmed in a report on Thursday, August 29th.

Institutional Trading of Insmed

Hedge funds have recently made changes to their positions in the stock. EntryPoint Capital LLC bought a new stake in Insmed in the first quarter worth $33,000. Fidelis Capital Partners LLC bought a new stake in Insmed during the 1st quarter valued at about $34,000. First Horizon Advisors Inc. raised its holdings in Insmed by 83.4% in the second quarter. First Horizon Advisors Inc. now owns 631 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 287 shares during the last quarter. Headlands Technologies LLC bought a new position in shares of Insmed in the first quarter worth approximately $59,000. Finally, CWM LLC increased its position in shares of Insmed by 11.0% during the second quarter. CWM LLC now owns 1,570 shares of the biopharmaceutical company’s stock valued at $105,000 after acquiring an additional 155 shares in the last quarter.

Insmed Price Performance

INSM stock opened at $71.04 on Wednesday. The company has a debt-to-equity ratio of 25.05, a quick ratio of 2.53 and a current ratio of 2.71. The firm has a market cap of $10.56 billion, a P/E ratio of -13.66 and a beta of 1.16. The firm’s fifty day moving average is $73.77 and its 200 day moving average is $48.45. Insmed has a 52 week low of $21.92 and a 52 week high of $80.53.

Insmed (NASDAQ:INSM) last released its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($1.94) EPS for the quarter, missing the consensus estimate of ($1.22) by ($0.72). The firm had revenue of $90.34 million during the quarter, compared to analysts’ expectations of $87.95 million. The company’s revenue for the quarter was up 17.0% on a year-over-year basis. During the same quarter in the prior year, the company posted ($1.78) EPS. Research analysts predict that Insmed will post -5.42 earnings per share for the current year.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.